Jazz Pharmaceuticals and AbCellera have entered into a preclinical research, option, and license agreement aimed at the discovery and development of T-cell engagers (TCEs) targeting gastrointestinal (GI) cancers and other solid tumors. This collaboration underscores the growing interest in multispecific antibodies as a therapeutic strategy in oncology, particularly in challenging solid tumor environments where traditional treatments often fall short.
The partnership leverages AbCellera’s advanced antibody discovery platform, which has demonstrated success in identifying novel therapeutic candidates. By focusing on T-cell engagers, the companies aim to enhance the immune system’s ability to recognize and attack cancer cells, potentially leading to more effective treatment options for patients with GI cancers and beyond. This agreement could pave the way for innovative therapies that address unmet medical needs in oncology, reflecting a broader trend in the pharmaceutical industry towards precision medicine and targeted therapies.
Open the full market picture for your next decision →
